Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Palbociclib in Hepatic Impairment
NCT02334800Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of palbociclib in breast cancer (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time at 192 hours and Maximum Plasma Concentration at 192 hours. Started Mar 2015; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02334800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334800.